Evicenter
MarkdownMedical informationP&T meetings
Barzolvolimab (CDX-0159)

Chronic spontaneous urticaria

Launch
Not announced
Last updated
177 sources

Clinical evidence

CDX0159-02

81 evidence topics · 12 sources

Objective
Location and study date
Registry dates and study sites in the United States and Germany
FieldQuoted record
Study start (actual)“2020-09-24”
Primary completion (actual)“2023-01-17”
Study completion (actual)“2023-01-17”
Countries of listed sites“United States”; “Germany”
Site in Germany“Charite University”
Study design
Eligibility criteria
Inclusion criteria: age, disease activity, disease duration, and antihistamine use

“Eligible patients were aged 18–75 years and had CSU refractory to H1 antihistamine at approved or increased doses alone or in combination with H2 antihistamine and/or leukotriene receptor antagonists (LTRA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Key inclusion criteria were moderate‐to‐severe CSU, defined as a weekly urticaria activity score (UAS7) of ≥ 16 (disease activity categories: 0, symptom free; 1–6, well‐controlled; 7–15, mild; 16–27, moderate; and 28–42, severe urticaria [11]); a weekly Hives Severity Score (HSS7) ≥ 8 (range: 0–21; higher values indicate greater severity) during the 7 days prior to randomization (Day 1); an in‐clinic UAS ≥ 4 on ≥ 1 screening visit days; antihistamine for treatment of CSU for at least 3 consecutive days immediately prior to the initial screening visit and were expected to use the antihistamines throughout the study period beginning at screening; CSU diagnosis for ≥ 6 months; and presence of itch and hives for ≥ 6 consecutive weeks at any time prior to enrollment despite concurrent use of antihistamine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Patients met defined hematology and chemistry criteria; had no other comorbidities that would introduce additional risk factors or interfere with study procedures; had no history of anaphylaxis; and had no known HIV, hepatitis B, or hepatitis C infection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Treatment
Study outcomes
Rationale for using incidence of adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics and baseline disease characteristics by cohort
Characteristic0.5 mg/kg Q4W (N = 9)1.5 mg/kg Q4W (N = 8)3.0 mg/kg Q8W (N = 9)4.5 mg/kg Q8W (N = 9)All barzolvolimab (N = 35)Pooled placebo (N = 10)
Age, years, mean (range)“43.8 (21–73)”View highlighted excerpt for this quote“53.3 (29–75)”View highlighted excerpt for this quote“49.4 (26–65)”View highlighted excerpt for this quote“51.1 (29–68)”View highlighted excerpt for this quote“49.3 (21–75)”View highlighted excerpt for this quote“49.8 (18–70)”View highlighted excerpt for this quote
Female, n (%)“6 (67)”View highlighted excerpt for this quote“7 (88)”View highlighted excerpt for this quote“6 (67)”View highlighted excerpt for this quote“9 (100)”View highlighted excerpt for this quote“28 (80)”View highlighted excerpt for this quote“7 (70)”View highlighted excerpt for this quote
BMI, kg/m2, mean (range)“31.1 (26.0–36.0)”View highlighted excerpt for this quote“37.8 (28.6–58.9)”View highlighted excerpt for this quote“29.4 (22.3–36.9)”View highlighted excerpt for this quote“27.1 (21.5–34.4)”View highlighted excerpt for this quote“31.2 (21.5–58.9)”View highlighted excerpt for this quote“31.8 (16.4–55.2)”View highlighted excerpt for this quote
CSU duration, years, mean (range)“7.5 (0.6–41.1)”View highlighted excerpt for this quote“17.1 (2.6–61.3)”View highlighted excerpt for this quote“4.8 (0.6–21.3)”View highlighted excerpt for this quote“10.4 (1.0–35.4)”View highlighted excerpt for this quote“9.7 (0.6–61.3)”View highlighted excerpt for this quote“5.6 (1.4–13.1)”View highlighted excerpt for this quote
Prior H2-antihistamine, n (%)“6 (67)”View highlighted excerpt for this quote“4 (50)”View highlighted excerpt for this quote“4 (44)”View highlighted excerpt for this quote“6 (67)”View highlighted excerpt for this quote“20 (57)”View highlighted excerpt for this quote“4 (40)”View highlighted excerpt for this quote
Prior leukotriene receptor antagonist, n (%)“3 (33)”View highlighted excerpt for this quote“2 (25)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote“3 (33)”View highlighted excerpt for this quote“8 (23)”View highlighted excerpt for this quote“2 (20)”View highlighted excerpt for this quote
Prior omalizumab, n (%)“4 (44)”View highlighted excerpt for this quote“3 (38)”View highlighted excerpt for this quote“4 (44)”View highlighted excerpt for this quote“2 (22)”View highlighted excerpt for this quote“13 (37)”View highlighted excerpt for this quote“6 (60)”View highlighted excerpt for this quote
UAS7, mean (range)“31.1 (20.0–39.0)”View highlighted excerpt for this quote“29.5 (20.0–40.6)”View highlighted excerpt for this quote“29.4 (16.3–42.0)”View highlighted excerpt for this quote“28.3 (22.0–38.0)”View highlighted excerpt for this quote“29.6 (16.3–42.0)”View highlighted excerpt for this quote“35.8 (19.0–42.0)”View highlighted excerpt for this quote
AAS7 positive at baseline, n (%)“5 (56)”View highlighted excerpt for this quote“6 (75)”View highlighted excerpt for this quote“7 (78)”View highlighted excerpt for this quote“8 (89)”View highlighted excerpt for this quote“26 (74)”View highlighted excerpt for this quote“5 (50)”View highlighted excerpt for this quote
AAS7 in those positive at baseline, mean (range)“29.0 (4.0–59.5)”View highlighted excerpt for this quote“43.3 (1.0–79.0)”View highlighted excerpt for this quote“29.8 (3.0–49.0)”View highlighted excerpt for this quote“33.7 (6.0–80.0)”View highlighted excerpt for this quote“34 (1.0–80.0)”View highlighted excerpt for this quote“53.2 (3.5–80.5)”View highlighted excerpt for this quote
UCT, mean (range)“1.7 (0–4)”View highlighted excerpt for this quote“2.4 (1–8)”View highlighted excerpt for this quote“3.1 (0–7)”View highlighted excerpt for this quote“4.7 (1–12)”View highlighted excerpt for this quote“3.0 (0–12)”View highlighted excerpt for this quote“3.4 (0–11)”View highlighted excerpt for this quote
Tryptase, ng/mL, mean (range)“5.0 (2.0–10.3)”View highlighted excerpt for this quote“6.3 (2.8–15.1)”View highlighted excerpt for this quote“8.6 (3.3–28.8)”View highlighted excerpt for this quote“5.5 (2.3–10.2)”View highlighted excerpt for this quote“6.2 (2.0–28.8)”View highlighted excerpt for this quote“5.3 (3.2–7.5)”View highlighted excerpt for this quote
Race, ISS7, HSS7, and total IgE at the November 2022 data cutoff
Baseline DLQI and PhysGA by cohort
Characteristic0.5 mg/kg Q4W (N= 9)1.5 mg/kg Q4W (N= 8)3.0 mg/kg Q8W (N= 9)4.5 mg/kg Q8W (N= 9)All barzolvolimab (N= 35)Pooled placebo (N= 10)
DLQI, mean (range)“13.2 (7-24)”“15.1 (5-24)”“7.8 (1-15)”“9.7 (1-16)”“11.3 (1-24)”“13.5 (1-26)”
PhysGA, mean (range)“1.9 (1-3)”“2.3 (1-3)”“2.7 (2-3)”“2.1 (1-3)”“2.2 (1-3)”“2.1 (1-3)”
Efficacy results
Health-related quality of life and patient-reported outcomes
Safety results
TEAEs in at least 10% of barzolvolimab-treated participants by cohort at 24 weeks
TEAE, n (%)0.5 mg/kg Q4W (N = 9)1.5 mg/kg Q4W (N = 8)3.0 mg/kg Q8W (N = 9)4.5 mg/kg Q8W (N = 9)All barzolvolimab (N = 35)Pooled placebo (N = 10)
Any TEAE“8 (89)”View highlighted excerpt for this quote“7 (88)”View highlighted excerpt for this quote“9 (100)”View highlighted excerpt for this quote“6 (67)”View highlighted excerpt for this quote“30 (86)”View highlighted excerpt for this quote“6 (60)”View highlighted excerpt for this quote
Neutropenia“2 (22)”View highlighted excerpt for this quote“2 (25)”View highlighted excerpt for this quote“1 (11)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote“5 (14)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote
Leukopenia“1 (11)”View highlighted excerpt for this quote“1 (13)”View highlighted excerpt for this quote“1 (11)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote“3 (9)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote
Diarrhea“1 (11)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote“1 (11)”View highlighted excerpt for this quote“1 (11)”View highlighted excerpt for this quote“3 (9)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote
Fatigue“1 (11)”View highlighted excerpt for this quote“1 (13)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote“1 (11)”View highlighted excerpt for this quote“3 (9)”View highlighted excerpt for this quote“1 (10)”View highlighted excerpt for this quote
Infections and infestations“1 (11)”View highlighted excerpt for this quote“4 (50)”View highlighted excerpt for this quote“5 (56)”View highlighted excerpt for this quote“4 (44)”View highlighted excerpt for this quote“14 (40)”View highlighted excerpt for this quote“2 (20)”View highlighted excerpt for this quote
COVID-19“0 (0)”View highlighted excerpt for this quote“1 (13)”View highlighted excerpt for this quote“2 (22)”View highlighted excerpt for this quote“2 (22)”View highlighted excerpt for this quote“5 (14)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote
Nasopharyngitis“0 (0)”View highlighted excerpt for this quote“1 (13)”View highlighted excerpt for this quote“2 (22)”View highlighted excerpt for this quote“1 (11)”View highlighted excerpt for this quote“4 (11)”View highlighted excerpt for this quote“1 (10)”View highlighted excerpt for this quote
Urinary tract infection“1 (11)”View highlighted excerpt for this quote“2 (25)”View highlighted excerpt for this quote“1 (11)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote“4 (11)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote
Arthralgia“2 (22)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote“1 (11)”View highlighted excerpt for this quote“3 (9)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote
Back pain“0 (0)”View highlighted excerpt for this quote“1 (13)”View highlighted excerpt for this quote“2 (22)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote“3 (9)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote
Headache“2 (22)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote“2 (22)”View highlighted excerpt for this quote“1 (11)”View highlighted excerpt for this quote“5 (14)”View highlighted excerpt for this quote“2 (20)”View highlighted excerpt for this quote
Hair color changes“0 (0)”View highlighted excerpt for this quote“1 (13)”View highlighted excerpt for this quote“3 (33)”View highlighted excerpt for this quote“5 (56)”View highlighted excerpt for this quote“9 (26)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote
Adverse events in at least 10% of barzolvolimab-treated participants, November 2022 data cutoff
AE, n (%)0.5 mg/kg Q4W (N= 9)1.5 mg/kg Q4W (N= 8)3.0 mg/kg Q8W (N= 9)4.5 mg/kg Q8W (N= 9)All barzolvolimab (N= 35)Pooled placebo (N= 10)
Any AE“8 (89)”“7 (88)”“9 (100)”“6 (67)”“30 (86)”“5 (50)”
Hair color changes“0 (0)”“1 (13)”“3 (33)”“4 (44)”“8 (23)”“0 (0)”
COVID-19“0 (0)”“1 (13)”“2 (22)”“2 (22)”“5 (14)”“0 (0)”
Headache“2 (22)”“0 (0)”“2 (22)”“1(11)”“5 (14)”“1 (10)”
Neutropenia“2 (22)”“2 (25)”“1 (11)”“0 (0)”“5 (14)”“0 (0)”
Urinary tract infection, cystitis, and bacteriuria“1 (11)”“2 (25)”“2 (22)”“0 (0)”“5 (14)”“0 (0)”
Urinary tract infection grouped with cystitis and bacteriuria in a later congress poster
AE, n (%)0.5 mg/kg Q4W (N= 9)1.5 mg/kg Q4W (N= 8)3.0 mg/kg Q8W (N= 9)4.5 mg/kg Q8W (N= 9)All barzolvolimab (N= 35)Pooled placebo (N= 10)
Urinary tract infection, cystitis, and bacteriuria“1 (11)”“3 (38)”“3 (33)”“0 (0)”“7 (20)”“0 (0)”
Study limitations
Summary
  • Author-stated limitations: “This study was limited by the small sample size and variation in drugs used for background urticaria treatment”, with participants required to be on a stable regimen before barzolvolimab administration.
  • Sample size and design: 45 participants were randomized, 35 to barzolvolimab in four sequentially enrolled cohorts of 8 or 9 and 10 to placebo pooled from each cohort (4:1 within cohorts). Analyses of pharmacokinetics, antidrug antibodies, and pharmacodynamics were descriptive.
  • Applicability of dosing: barzolvolimab was given as a 60-minute intravenous infusion at 0.5 to 4.5 mg/kg every 4 or 8 weeks for 12 weeks; the phase 3 trials use subcutaneous 150 mg every 4 weeks or 300 mg every 8 weeks after a loading dose. The registry title calls the study phase 1, and the publication calls it phase 1b.
  • Follow-up and missing data: follow-up lasted 12 weeks or until symptoms resumed. Company responder analyses excluded participants with missing data at a timepoint and showed Week 24 only for dose levels with at least 50% of participants with data; data for 0.5 mg/kg and placebo were included only through week 12 because most of those participants had significant symptoms ahead of week 24 and discontinued follow up. Two placebo participants did not complete treatment because they sought alternate treatment for symptom severity.
  • Baseline differences: mean UAS7 was 35.8 in the placebo group and 29.6 in the barzolvolimab group, and prior omalizumab was recorded in 6 (60%) placebo and 13 (37%) barzolvolimab participants in Table 1; the publication states there were no notable differences between groups at baseline.
  • Antidrug antibodies, by document: 57% (20/35) in the publication; 51% in the November 2022 data cutoff poster.
  • Hair color changes, by document: 9 (26%) in the publication; 8 (23%) in the November 2022 poster.
  • Any adverse event with placebo, by document: 6 (60%) in the publication; 5 (50%) in the November 2022 poster.
  • Urinary tract infection, by document: 4 (11%) in the publication; 5 (14%) in the November 2022 poster and 7 (20%) in the EADV 2023 poster, both of which group urinary tract infection, cystitis, and bacteriuria.
  • Prior omalizumab, by document: 44% in the publication's summary statement; 37% of treated participants in the company release reporting the November 2022 data cutoff; 42% of barzolvolimab-treated participants at the May 2022 data cutoff.
  • Baseline AAS7, by document: 26.6 (placebo) and 26.0 (barzolvolimab) in the publication text; 53.2 (placebo) and 34 (barzolvolimab) among participants AAS7 positive at baseline in Table 1.
  • Disposition, by document: three participants did not complete the treatment period (publication); two did not receive all doses of study treatment (company release reporting the November 2022 data cutoff).
  • The omalizumab-experienced subgroup at pooled doses of 1.5 mg/kg or more is n=9 in the EAACI 2023 poster.
  • Sponsor role: the trial was designed and sponsored by Celldex Therapeutics, data were analyzed by the sponsor, and the first draft of the manuscript was written by a medical writer paid by the sponsor.
  • External comparison: the publication sets the 57% Week 12 complete response beside 36% for omalizumab 300 mg Q4W in registrational trials at 12 weeks.